10-K: Humana Inc. 2023 Annual Report: Strategic Realignment and Financial Performance

Humana's 2023 annual report highlights a strategic realignment into Insurance and CenterWell segments, alongside financial results impacted by various factors including Medicare Advantage utilization and strategic initiatives.

Summary

• Humana Inc.'s 2023 annual report details a strategic shift into two main segments: Insurance and CenterWell.
• The Insurance segment includes Medicare, state-based contracts, commercial fully-insured, specialty benefits, and military services.
• The CenterWell segment focuses on healthcare services like pharmacy, primary care, and home solutions.
• In 2023, 84% of Humana's revenue came from federal government contracts, with 14% specifically from individual Medicare Advantage contracts in Florida covering approximately 851,300 members.
• The company reported approximately 17 million members in medical benefit plans and 5 million in specialty products as of December 31, 2023.
• Net income attributable to Humana was $2.5 billion, or $20.00 per diluted common share, in 2023, compared to $2.8 billion, or $22.08 per diluted common share, in 2022.
• The 2023 results were impacted by a gain on sale of Gentiva Hospice, put/call valuation adjustments, transaction costs, changes in fair value of equity securities, litigation expenses, value creation initiatives, and impairment charges.
• The company is exiting the Employer Group Commercial Medical Products business over 18 to 24 months following a February 2023 announcement.
• Humana is actively involved in the care management of customers with the greatest needs via in-home care, with 14% of MA members served by their value-based model as of December 31, 2023.
• The company has a strategic partnership with Welsh, Carson, Anderson & Stowe to develop and operate senior-focused primary care centers, with 108 clinics operating under the partnership as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strategic realignment and growth in certain areas, there are also significant challenges and financial headwinds. The exit from a major business line and the higher than anticipated medical costs are concerning, but the company is taking steps to address these issues. The sentiment is neutral to slightly negative.

Positives

• Humana has a strong presence in the Medicare market, offering plans in all 50 states.
• The company is expanding its integrated care delivery model, which aims to improve health outcomes and affordability.
• Humana is growing its CenterWell segment, which includes pharmacy, primary care, and home solutions.
• The company has a large and diverse membership base, which provides opportunities for growth.
• Humana is actively involved in the care management of customers with the greatest needs via in-home care.
• The company has a strategic partnership with Welsh, Carson, Anderson & Stowe to develop and operate senior-focused primary care centers.

Negatives

• Humana is exiting the Employer Group Commercial Medical Products business, which will result in a loss of revenue.
• The company experienced higher than anticipated Medicare Advantage utilization trends in 2023, particularly in the fourth quarter.
• The company's net income decreased in 2023 compared to 2022 due to various factors.
• The company is subject to various legal actions and governmental investigations, which could result in substantial monetary damages or changes in business practices.
• The company is subject to substantial government regulation, which could increase the cost of doing business.

Risks

• The company's profitability may be materially adversely affected if it does not design and price its products properly and competitively.
• The company is in a highly competitive industry, and some of its competitors have a larger membership base and/or greater financial resources.
• The policies and decisions of the federal and state governments regarding the Medicare Advantage and Prescription Drug Plans, military services and Medicaid programs in which the company participates have a substantial impact on its profitability.
• If the company fails to effectively implement its operational and strategic initiatives, its business may be materially adversely affected.
• If the company fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems, or to protect its proprietary rights to its systems, its business may be materially adversely affected.
• If the company is unable to defend its information technology systems against cybersecurity attacks, it could be exposed to significant regulatory fines or penalties, liability or reputational damage.
• As a government contractor, the company is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government health care programs.
• The company is subject to various governmental audits and investigations, which could result in the loss of licensure or temporary or permanent exclusion from participating in various government health care programs.
• The company is subject to various federal and state healthcare fraud and abuse laws, including the federal False Claims Act, the federal anti-kickback statute, and the federal Stark Law.
• The company's ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.
• Downgrades in the company's debt ratings may adversely affect its business, results of operations, and financial condition.
• Volatility or disruption in the securities and credit markets, including changes in interest rates, may significantly and adversely affect the value of the company's investment portfolio and the investment income that it derives from this portfolio.

Future Outlook

The company anticipates a net membership growth in individual Medicare Advantage offerings of approximately 100,000 members, a net membership growth in group Medicare Advantage offerings of approximately 45,000 members, a net membership decline in Medicare stand-alone PDP offerings of approximately 650,000 members, and a net membership growth in state-based contracts of approximately 250,000 members for the full year 2024.

Management Comments

• Humana Inc. is committed to putting health first for our teammates, our customers, and our company.
• Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health delivering the care and service they need, when they need it.
• These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large.

Industry Context

The health benefits industry is highly competitive, with competitors including other managed care companies, national insurance companies, and other HMOs and PPOs. Many of these competitors have a larger membership base and/or greater financial resources than Humana in some markets. The company also faces competition from emerging competitors in the Medicare program and competitors in the delivery of health care services.

Comparison to Industry Standards

• Humana's benefit ratio of 87.3% is within the range of other large health insurers, but the increase of 100 basis points from 2022 indicates a trend of higher medical costs.
• The operating cost ratio of 12.5% is competitive, reflecting the company's efforts to manage administrative expenses.
• The company's strategic shift towards value-based care aligns with industry trends, but the success of this model will depend on its ability to manage costs and improve health outcomes.
• The company's exit from the Employer Group Commercial Medical Products business is a significant strategic move, which is not common among large health insurers and may impact its competitive position in the short term.
• The company's focus on Medicare Advantage and state-based contracts reflects the growing importance of these markets in the healthcare industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is party to a variety of legal actions in the ordinary course of business, certain of which may be styled as class-action lawsuits.
• The company is subject to a variety of legal actions relating to its business operations, including the design, management, and offering of products and services.
• The company is involved in a qui tam suit alleging civil violations in connection with the actuarial equivalence of the plan benefits under Humana's Basic PDP plan.
• The company filed suit against the United States Department of Health and Human Services regarding the Final RADV Rule.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and the higher than anticipated medical costs.
• Employees may be affected by the company's exit from the Employer Group Commercial Medical Products business and the workforce optimization initiatives.
• Customers may be affected by changes in the company's product offerings and service delivery.
• Providers may be affected by changes in the company's provider networks and payment models.
• Suppliers may be affected by changes in the company's supply chain and procurement practices.
• Creditors may be affected by changes in the company's financial performance and credit ratings.

Next Steps

• The company will continue to implement its strategic initiatives, including the expansion of its Medicare programs and the growth of its CenterWell businesses.
• The company will continue to manage its operating expenses and improve its financial performance.
• The company will continue to monitor and respond to changes in the regulatory environment.
• The company will continue to work alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for its members.

Key Dates

Keywords

Medicare Advantage, healthcare services, insurance, CenterWell, pharmacy solutions, primary care, home solutions, government contracts, risk adjustment, Medicaid, TRICARE, financial performance, strategic realignment